Avid Bioservices Inc (CDMO)

[Threes]

If we recognize the $8 million from oncologie we will net profit of 2 million against $900 million in losses to write off. First year ever profit of .05 Per Share. Based on projected loss from operations of .15 for FY 2019. Q1 2019 begins May 1.

The more important issue will be rev's, projections, backlog with expanded client base.
In the meantime waiting on confirming PR for recently PR'd pending contracts at AVID.
I appreciate the terms of the new structured contract's They put skin in the game for their clients and relieve "lumpiness" we had with rev's in the past. Improved cash flow and predictability.

We will have some insight if PS was shelved by orders for Bavi from Oncologie with AVID.